Approach to Management of Inflammatory Bowel Disease-Related Arthritis

Authors

  • May Y. Choi, MD, MPH, FRCPC Cumming School of Medicine, University of Calgary
  • Dianne Mosher, MD Cumming School of Medicine, University of Calgary

DOI:

https://doi.org/10.58931/cibdt.2023.118

Keywords:

spondyloarthritis, inflammatory bowel disease

Abstract

The most common extraintestinal manifestation of inflammatory bowel disease (IBD) is arthropathy. These conditions have been reported in up to 50% of patients with IBD and are more common in Crohn’s’ disease (CD), particularly colonic disease, and in females.

IBD-associated arthritis is classified as a type of spondyloarthritis (SpA). The treatment is dependent on the type of SpA involvement, which can be subdivided into peripheral and/or axial disease. The treatment approach consists of a combination of non-pharmacological and pharmacological therapies managed by a multidisciplinary team and is based on collaborative decisions between gastroenterology and rheumatology. In light of rapidly expanding therapeutic armamentaria for both immune-mediated arthritis and IBD, this paper will provide an overview of an approach to the treatment of arthritis associated with IBD, considering recommendations by recent guidelines and novel therapies.

Author Biographies

May Y. Choi, MD, MPH, FRCPC, Cumming School of Medicine, University of Calgary

Dr. May Choi is a rheumatologist and clinician scientist who started on faculty as an Assistant Professor at the Cumming School of Medicine, University of Calgary in 2020, and is a Member of the McCaig Institute for Bone and Joint Health. As an early career investigator, her research is focused on biomarker discovery and validation for prediction of clinical outcomes in autoimmune rheumatic diseases, and the prevention of autoimmune disease development and disease-related complications. She leads a research laboratory and biobank for local, national, and international collaborators. Her background and training include a Masters of Public Health in Epidemiology at Harvard University and a lupus fellowship at the Brigham and Women’s Hospital (Boston, MA) under the supervision of Dr. Karen Costenbader (epidemiologist, lupus expert and Professor of Medicine at Harvard Medical School). Dr. Choi is also the Associate Director of MitogenDx Laboratory for novel autoantibody and biomarker testing for autoimmune diseases and the Associate Director of Research for the University of Calgary Lupus Centre of Excellence, which complement her research.

Dianne Mosher, MD, Cumming School of Medicine, University of Calgary

Dr. Dianne Mosher is the Associate Dean of Indigenous, Local and Global Health and Professor of Medicine at the Cumming School of Medicine, University of Calgary. She is the past president of the Canadian Rheumatology Association and the Arthritis Alliance of Canada. She has over 30 years of clinical experience in Rheumatology with expertise in spondyloarthritis and Indigenous Health. Her research area of interest is in clinical outcomes, models of care, and system-level change.

References

Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239- 54. DOI: https://doi.org/10.1093/ecco-jcc/jjv213

de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol. 2000;27(12):2860-5.

Lanna CC, Ferrari Mde L, Rocha SL, Nascimento E, de Carvalho MA, da Cunha AS. A cross-sectional study of 130 Brazilian patients with Crohn’s disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations. Clin Rheumatol. 2008;27(4):503-9. DOI: https://doi.org/10.1007/s10067-007-0797-5

Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol. 2002;29(3):511-5.

Salvarani C, Vlachonikolis IG, van der Heijde DM, Fornaciari G, Macchioni P, Beltrami M, et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol. 2001;36(12):1307-13. DOI: https://doi.org/10.1080/003655201317097173

Turkcapar N, Toruner M, Soykan I, Aydintug OT, Cetinkaya H, Duzgun N, et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int. 2006;26(7):663-8. DOI: https://doi.org/10.1007/s00296-005-0044-9

Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777-83. DOI: https://doi.org/10.1136/ard.2009.108233

Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25-31. DOI: https://doi.org/10.1136/ard.2010.133645

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599-613. DOI: https://doi.org/10.1002/art.41042

van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. DOI: https://doi.org/10.1136/annrheumdis-2016-210770

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016;68(5):1060-71. DOI: https://doi.org/10.1002/art.39573

Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42(3):387-91. DOI: https://doi.org/10.1136/gut.42.3.387

Kehl AS, Corr M, Weisman MH. Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment. Arthritis Rheumatol. 2016;68(2):312-22. DOI: https://doi.org/10.1002/art.39458

Evans J, Sapsford M, McDonald S, Poole K, Raine T, Jadon DR. Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross- sectional imaging: a systematic literature review. Ther Adv Musculoskelet Dis. 2021;13:1759720X21996973. DOI: https://doi.org/10.1177/1759720X21996973

Steer S, Jones H, Hibbert J, Kondeatis E, Vaughan R, Sanderson J, et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. J Rheumatol. 2003;30(3):518-22.

Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra- articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65-73. DOI: https://doi.org/10.1136/annrheumdis-2013-203582

Stolwijk C, Essers I, van Tubergen A, Boonen A, Bazelier MT, De Bruin ML, et al. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis. 2015;74(7):1373-8. DOI: https://doi.org/10.1136/annrheumdis-2014-205253

Cypers H, Varkas G, Beeckman S, Debusschere K, Vogl T, Roth J, et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2016;75(7):1357-62. DOI: https://doi.org/10.1136/annrheumdis-2015-208025

Van Praet L, Van den Bosch FE, Jacques P, Carron P, Jans L, Colman R, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013;72(3):414-7. DOI: https://doi.org/10.1136/annrheumdis-2012-202135

Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G. Nonsteroidal anti- inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002;46(1):1-6. DOI: https://doi.org/10.1016/S1043-6618(02)00033-6

Cohen-Mekelburg S, Van T, Wallace B, Berinstein J, Yu X, Lewis J, et al. The Association Between Nonsteroidal Anti-Inflammatory Drug Use and Inflammatory Bowel Disease Exacerbations: A True Association or Residual Bias? Am J Gastroenterol. 2022;117(11):1851-7. DOI: https://doi.org/10.14309/ajg.0000000000001932

Moninuola OO, Milligan W, Lochhead P, Khalili H. Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti- inflammatory drugs (NSAIDs) and risk of Crohn’s disease and ulcerative colitis exacerbation. Aliment Pharmacol Ther. 2018;47(11):1428-39. DOI: https://doi.org/10.1111/apt.14606

Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(6):751-7. DOI: https://doi.org/10.1097/00054725-200411000-00009

Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 1;13(1):50-57. doi:10.1093/ecco-jcc/jjy125 DOI: https://doi.org/10.1093/ecco-jcc/jjy125

Dougados M, Combe B, Braun J, Landewe R, Sibilia J, Cantagrel A, et al. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis. 2010;69(8):1430-5. DOI: https://doi.org/10.1136/ard.2009.121533

Mourad A, Gniadecki R. Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis. J Rheumatol. 2020;47(1):59-65. DOI: https://doi.org/10.3899/jrheum.180797

Regnaux JP, Davergne T, Palazzo C, Roren A, Rannou F, Boutron I, et al. Exercise programmes for ankylosing spondylitis. Cochrane Database Syst Rev. 2019;10(10):CD011321. DOI: https://doi.org/10.1002/14651858.CD011321.pub2

van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394(10214):2108-17. DOI: https://doi.org/10.1016/S0140-6736(19)32534-6

Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo- controlled, phase 3 trial. Lancet. 2022;400(10349):369-79. DOI: https://doi.org/10.1016/S0140-6736(22)01212-0

Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258-70. DOI: https://doi.org/10.1002/art.40728

Gold SL, Steinlauf AF. Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature. Gastroenterol Hepatol (N Y). 2021;17(9):406-14.

Downloads

Published

2023-04-11

How to Cite

1.
Choi MY, Mosher D. Approach to Management of Inflammatory Bowel Disease-Related Arthritis. Can IBD Today [Internet]. 2023 Apr. 11 [cited 2024 May 18];1(1):25–30. Available from: https://canadianibdtoday.com/article/view/1-1-4-choi_et_al

Issue

Volume 1, Issue 1, April 2023

Section

Articles

License

Copyright (c) 2023 Canadian IBD Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.